Amneal Pharmaceuticals Inc

AMRX remains in a Stage 2 advance with strong higher highs/lows and rising EMAs. The medium-term bias is bullish, but price is extended above the 9/21/50 EMA cluster and overbought. Execution is deferred: look to engage on a pullback into the rising EMA support zone for continuation participation.

• ↑Forecasted 20.5% FY earnings growth backed by multiple product approvals.
• ↑Q1 revenue $720M (+3% YoY), adjusted EBITDA $184M (+13%), EPS $0.45 (+56%).
• ↓High leverage and 13F outflows indicate institutional skepticism on stability.